Soc. Generale Knock-Out MRK 21.06.../ DE000SU630U7 /
6/3/2024 4:06:15 PM | Chg.+0.200 | Bid6/3/2024 | Ask6/3/2024 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
9.800EUR | +2.08% | 9.800 Bid Size: 6,000 |
10.000 Ask Size: 6,000 |
MERCK KGAA O.N. | - EUR | 6/21/2024 | Call |
GlobeNewswire
2:00 PM
Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX...
GlobeNewswire
2:38 AM
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pe...
GlobeNewswire
5/29
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
5/7
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
5/6
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
3/4
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
12/21/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
12/14/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
10/17/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA